Document is current
Any future updates will be listed below
-
Authors
Maas, Carolien C. H. M. https://orcid.org/0000-0002-3867-2465
van Klaveren, David
Durmaz, Müjde https://orcid.org/0000-0002-5724-1484
Visser, Otto
Issa, Djamila E.
Posthuma, Eduardus F. M.
Zijlstra, Josée M.
Chamuleau, Martine E. D. https://orcid.org/0000-0002-0123-9182
Lugtenburg, Pieternella J.
Kersten, Marie José https://orcid.org/0000-0002-8904-3802
Dinmohamed, Avinash G. https://orcid.org/0000-0002-4767-6716
- License Information
-
More Information
Article History
Received: 18 June 2024
Revised: 29 August 2024
Accepted: 2 September 2024
First Online: 12 September 2024
Competing interests
: PJL reports research funding to institution: Takeda; Consultancy honoraria: Y-mAbs-Therapeutics; Sandoz; Bristol Meyer Squibb; Speaker honoraria: Roche, AbbVie, Lilly; Honoraria for advisory board: Roche, Genmab, AbbVie; Travel support: Sanofi. MJK reports honoraria from and consulting/advisory role for BMS/Celgene, Kite, a Gilead Company, Miltenyi Biotec, Adicet Bio, Mustang Bio, Novartis, and Roche; research funding from Kite, a Gilead Company, and travel support from Kite, a Gilead Company, Abbvie and Roche.
